Intellectual Property Portfolio Significantly Broadened for Its Proprietary Transdermal Delivery System...

Continues to Progress Clinical Trial; Patents for Proprietary Platform to Develop New Women's Contraceptive Products Allowed...

PRINCETON, N.J. , Aug. 27, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that management will present at the following...

Company on Track to Complete Study Enrollment for Its Combined Hormonal Contraceptive Patch by the End of Third Quarter 2015...

PRINCETON, N.J. , Sept. 3, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (NASDAQ:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Al Altomari , President and Chief...

Company Plans to Complete Clinical Trial in the Second Half of 2016 and File its Resubmission to the FDA in First Half of 2017...

Completion of the SECURE Clinical Trial for Twirla® Planned for Second Half of 2016; Resubmission to the FDA Planned for the First Half of 2017...

PRINCETON, N.J., Nov. 17, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Al Altomari, President and Chief Executive...

PRINCETON, N.J., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that it has received net proceeds of approximately $6 million in...

Presentation Scheduled on Monday, January 18, 2016 at 11:30 AM ET ...